Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAmphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
Journal of Clinical Oncology, 09/11/09
Jacobs B et al. – Expression of EGFR ligands in primary tumors significantly predicts outcome in KRAS WT cmCRC treated with cetuximab and irinotecan.
Methods- Gene expression measurements and KRAS mutation analysis were performed on archival formalin-fixed paraffin-embedded primary tumors of 220 cmCRC patients
- Response was measured using RECIST criteria
- Findings were externally validated on a series of 67 samples treated in a similar setting
- In KRAS w/t patients, there was a significant association between log-transformed ligand expression and response for EREG (OR for objective response, 1.90; concordance index [c-index], 0.681) and for AREG (OR for objective response, 1.862; c-index, 0.673)
- Dichotomized ligand expression was significantly associated with PFS and OS
- EREG PFS HR was 0.41 and AREG PFS HR was 0.43
- EREG OS HR was 0.42 and AREG OS HR was 0.40
- There was no predictive power of ligand expression in patients with KRAS mutation
Related Articles
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer
British Journal of Cancer, 11/20/09
Relevance Score: 83%
Gender Disparities in Metastatic Colorectal Cancer Survival
Clinical Cancer Research, 10/06/09
Relevance Score: 82%
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
Journal of Cancer Research & Clinical Oncology, 11/18/09
Relevance Score: 81%
New trends in epidermal growth factor receptor-directed monoclonal antibodies
Immunotherapy, 11/06/09
Relevance Score: 81%
Optimizing the management of metastatic colorectal cancer
Critical Reviews in Oncology/Hematology, 10/23/09
Relevance Score: 81%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Gene expression markers for genetic risk groups and survival in chronic lymphocytic leukemia
Haematologica, 12/03/09
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
British Journal of Cancer, 12/03/09
Menthol induces cell death via the TRPM8 channel in the human bladder cancer cell line T24
Oncology (Karger), 12/03/09
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
British Journal of Cancer, 12/03/09
Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver
The Oncologist, 12/03/09
Predictors of endoscopic colorectal cancer screening over time in 11 states
Cancer Causes and Control, 12/03/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Melphalan 200 mg/m2 versus Melphalan 100 mg/m2 in newly diagnosed myeloma patients: A prospective, multi-center phase III study
Blood, 12/03/09
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/03/09
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
British Journal of Cancer, 12/03/09
Sponsor
Article Search
Sponsor
Sponsor